TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25616941

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - 10 minutes of inflow occlusion followed by 10 minutes of reperfusion before liver transection
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Anesthetic preconditioning (APC) - sevoflurane administration for 20 minutes before liver transection
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intermittent clamping (INT) - no preconditioning
Number of subjects: 106
Study: 23095710

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg•kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 40
Study: 21764136

Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg (n = 341)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg (n = 412)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Sham (n = 423)
Number of subjects: 1256
Study: 19454187

Group type: EXPERIMENTAL
Intervention: Children with type 1 diabetes (T1D)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 25
Study: 16684170

Group type: COMPARATOR
Intervention: Written materials on sexual dysfunction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Written materials plus three counselling sessions
Number of subjects: 62
Study: 14872476

Group type: EXPERIMENTAL
Intervention: 50 mg etanercept once weekly
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 25 mg etanercept twice weekly
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 12412825

Group type: EXPERIMENTAL
Intervention: Tilidine 50 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tilidine 50 mg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortilidine 10 mg intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tilidine (both oral and intravenous)
Number of subjects: 0
Study: 9584558

Group type: EXPERIMENTAL
Intervention: Anti-emetic therapy
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Quality of life assessment on day 3
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Quality of life assessment on day 8 with 7 day time frame
Number of subjects: 650
Study: 7544515

Group type: EXPERIMENTAL
Intervention: Various case definitions of benign prostatic hyperplasia (BPH) based on clinical parameters
Number of subjects: 502
Study: 2669225

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 9
Study: 183790

Group type: EXPERIMENTAL
Intervention: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S) at a dosage of 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S) at a dosage of 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticotrophin-(1-23)-tricosipeptide-amide (Acethropan S)
Number of subjects: 0
Study: 27904985

Group type: EXPERIMENTAL
Intervention: Intervention to enhance occupational physicians' guideline adherence
Number of subjects: 3379

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3379
Study: 25965711

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 700

Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 700
Study: 22554106

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study: 21091135

Group type: EXPERIMENTAL
Intervention: Haptic device for robotic-assisted fine-motor training
Number of subjects: 21
Study: 19740730

Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17926610

Group type: EXPERIMENTAL
Intervention: New Bian-stone therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 240
Study: 15819300

Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 11875680

Group type: COMPARATOR
Intervention: Ayurvedic cutting seton (C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional fistulotomy (F)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (F and C)
Number of subjects: 108
Study: 9046395

Group type: EXPERIMENTAL
Intervention: Bonded acrylic expander
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hyrax appliance
Number of subjects: 14
Study: 7943082

Group type: EXPERIMENTAL
Intervention: Preterm labor group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Premature rupture of membranes group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 30871361

Group type: EXPERIMENTAL
Intervention: Monacolin K-rich RYR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GABA-rich RYR
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28721957

Group type: EXPERIMENTAL
Intervention: Regular users of MDM Programme
Number of subjects: 322

Group type: COMPARATOR
Intervention: Occasional/never users of MDM Programme
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Children born with <2.5 kg
Number of subjects: 322
Study: 25469829

Group type: EXPERIMENTAL
Intervention: 33G needle
Number of subjects: 87

Group type: COMPARATOR
Intervention: 32G needle
Number of subjects: 87
Study: 22925113

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (2 mg/0.08 mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No medical treatment (Control)
Number of subjects: 22
Study: 21831512

Group type: EXPERIMENTAL
Intervention: PSD503 (phenylephrine 20%, w/w)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18082208

Group type: EXPERIMENTAL
Intervention: Daily cotrimoxazole
Number of subjects: 225

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 225
Study: 17415419

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine drug therapy
Number of subjects: 0
Study: 14520029

Group type: EXPERIMENTAL
Intervention: Combined manipulation, stabilizing exercises, and physician consultation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Physician consultation alone
Number of subjects: 204
Study: 10631856

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 9180313

Group type: EXPERIMENTAL
Intervention: Cement gun technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Finger-packing technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laboratory model (not specified as intervention or control)
Number of subjects: 50
Study: 1489026

Group type: EXPERIMENTAL
Intervention: Extradural infusion of lignocaine 0.75% after an initial dose of 10 ml of lignocaine 1.5%
Number of subjects: 86

Group type: COMPARATOR
Intervention: Extradural infusion of bupivacaine 0.125% after an initial dose of 10 ml of bupivacaine 0.25%
Number of subjects: 86
Study: 2412043

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 17
Study: 30536638

Group type: EXPERIMENTAL
Intervention: Golimumab (subcutaneous administration)
Number of subjects: 0
Study: 30431325

Group type: EXPERIMENTAL
Intervention: Virtual laboratory
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Blended group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Living tissue laboratory
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Blended style
Number of subjects: 63
Study: 27378612

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump therapy
Number of subjects: 758

Group type: COMPARATOR
Intervention: Control group (no intraaortic balloon pump therapy)
Number of subjects: 758
Study: 25047592

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by Azathioprine (AZA)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Open-label RTX
Number of subjects: 197
Study: 22267573

Group type: EXPERIMENTAL
Intervention: Exercise group (therapeutic exercises)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard group (no additional exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-injured control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard group vs Non-injured control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise group vs Non-injured control group
Number of subjects: 0
Study: 20070145

Group type: EXPERIMENTAL
Intervention: Feldenkrais exercises (FG group, n = 25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (CG, n = 22)
Number of subjects: 47
Study: 17426300

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 20000000

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 20000000

Group type: EXPERIMENTAL
Intervention: Inhaled dry powdered insulin (IDPI)
Number of subjects: 20000000
Study: 15618027

Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg bid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12503340

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg i.v. or p.o. twice daily (400 mg twice daily for uncomplicated skin and skin-structure infections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study: 10455471

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study: 8590781

Group type: EXPERIMENTAL
Intervention: Structured teaching/treatment programme
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional diabetes treatment (control group)
Number of subjects: 79
Study: 2218875

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy plus adjuvant litholytic therapy with ursodeoxycholic acid (UDCA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (extracorporeal shock-wave lithotripsy)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: UDCA for patients with solitary stones ≤20 mm
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo for patients with solitary stones ≤20 mm
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy
Number of subjects: 133
Study: 895429

Group type: EXPERIMENTAL
Intervention: 80% O2‐20% N2
Number of subjects: 12
Study: 31238871

Group type: EXPERIMENTAL
Intervention: Patient-centered communication and shared decision making intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study: 28947022

Group type: EXPERIMENTAL
Intervention: FF/UMEC 62.5 mcg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: FF/UMEC 125 mcg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: FF/UMEC (all doses)
Number of subjects: 338

Group type: COMPARATOR
Intervention: FF (Control)
Number of subjects: 338
Study: 25294090

Group type: EXPERIMENTAL
Intervention: sugar-free Red Bull (sfRB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: water + 120 mg caffeine
Number of subjects: 8

Group type: COMPARATOR
Intervention: water + placebo
Number of subjects: 8
Study: 23988781

Group type: EXPERIMENTAL
Intervention: Multiple-pass hemoconcentration (MPH)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Centrifugation (CF)
Number of subjects: 61
Study: 21539731

Group type: EXPERIMENTAL
Intervention: Small-scale living facilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional nursing homes
Number of subjects: 0
Study: 20057195

Group type: EXPERIMENTAL
Intervention: Combined DAK therapy for obesity (inpatient therapy for 6 weeks followed by home-based outpatient treatment for 10.5 months)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (waiting list subjects)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Combined DAK therapy for obesity
Number of subjects: 162
Study: 17413047

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for up to 14 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12845405

Group type: EXPERIMENTAL
Intervention: METH (10 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stress (Trier Social Stress Test)
Number of subjects: 28

Group type: COMPARATOR
Intervention: METH (10 mg) with Stress
Number of subjects: 28
Study: 12563720

Group type: EXPERIMENTAL
Intervention: Zyrtec (Cetirizine 2 HCL) drops 5 mg daily for 3 weeks
Number of subjects: 47
Study: 10170452

Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors
Number of subjects: 30
Study: 8445848

Group type: EXPERIMENTAL
Intervention: Once daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 4.97 +/- 1.12 mg/kg (total dosage per exacerbation: 74.55 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thrice daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 9.60 +/- 2.70 mg/kg (total dosage per exacerbation: 165.12 mg/kg)
Number of subjects: 26
Study: 3522422

Group type: EXPERIMENTAL
Intervention: Alcohol-loaded beer
Number of subjects: 16
Study: 31735057

Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non‐specific Supportive Clinical Management
Number of subjects: 100
Study: 30229883

Group type: EXPERIMENTAL
Intervention: Pythagorean Self‐Awareness Intervention (PSAI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 29336896

Group type: EXPERIMENTAL
Intervention: Combination therapy with 0.3 mg ranibizumab and TRP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monotherapy with 0.3 mg ranibizumab
Number of subjects: 40
Study: 26808532

Group type: EXPERIMENTAL
Intervention: Intentional weight loss of 1 kg/year
Number of subjects: 761
Study: 24257718

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee high in chlorogenic acid (C-HCA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee high in chlorogenic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with regular amounts of chlorogenic acid (D-RCA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High fructose diet
Number of subjects: 10
Study: 21952267

Group type: EXPERIMENTAL
Intervention: Baseline physical activity
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: More social support for physical activity
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Employees from the second worksite
Number of subjects: 642
Study: 19410973

Group type: EXPERIMENTAL
Intervention: Short-chain fructo-oligosaccharides (sc-FOS) 10 g daily for 36 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 14
Study: 17468494

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 26
Study: 15470373

Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11952442

Group type: EXPERIMENTAL
Intervention: Intradermal patent blue vital dye (PBV) sentinel node marking
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PBV used)
Number of subjects: 20
Study: 10753434

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (0.2 ml of a 4-mg/ml dexamethasone solution, 0.8 mg per injection)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Normal saline injection (control group)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Various medical treatments (central vasodilators, vestibular suppressants, calcium channel blockers, anticholinergic drugs, anticonvulsant drugs, gingko biloba)
Number of subjects: 500
Study: 7796901

Group type: EXPERIMENTAL
Intervention: Sexually experienced males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexually experienced females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 0
Study: 2189668

Group type: EXPERIMENTAL
Intervention: TRUE Test, Panel 2
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control method
Number of subjects: 808
Study: 631966

Group type: EXPERIMENTAL
Intervention: Plain xanthinol nicotinate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Slow-release xanthinol nicotinate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30657348

Group type: EXPERIMENTAL
Intervention: Prophylactic HPV vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender-neutral HPV vaccination
Number of subjects: 0
Study: 28170117

Group type: EXPERIMENTAL
Intervention: Cervical pessary placement (Bioteque™ cup)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No pessary
Number of subjects: 46
Study: 25881589

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment for 10 days followed by esomeprazole 20 mg bid for 46 days
Number of subjects: 356

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg bid therapy for 8 weeks (control group)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: H. pylori positive uneradicated group
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: H. pylori negative group
Number of subjects: 356
Study: 23962400

Group type: EXPERIMENTAL
Intervention: 15 min brisk walking
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 41
Study: 21919735

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring plus problem-solving counseling
Number of subjects: 29

Group type: COMPARATOR
Intervention: Continuous glucose monitoring plus education
Number of subjects: 29
Study: 19377796

Group type: EXPERIMENTAL
Intervention: Acute exercise at 90% of anaerobic threshold (AT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acute exercise at 60% of anaerobic threshold (AT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acute exercise at 110% of anaerobic threshold (AT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All trial groups (60%, 90%, 110% of AT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (without exercise)
Number of subjects: 48
Study: 17936918

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg kg(‐1) + alfentanil 0.02 mg kg(‐1) + rocuronium 0.45 mg kg(‐1)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1) + alfentanil 0.02 mg kg(‐1) + rocuronium 0.45 mg kg(‐1)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Propofol 3.0 mg kg(‐1) + alfentanil 0.02 mg kg(‐1) + rocuronium 0.45 mg kg(‐1)
Number of subjects: 111
Study: 15235345

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (IT-DEX)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 39
Study: 11226989

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler sonography (PDS) for strangulating obstruction
Number of subjects: 117

Group type: COMPARATOR
Intervention: Pulsed Doppler sonography (PDS) for simple obstruction
Number of subjects: 117
Study: 9560861

Group type: EXPERIMENTAL
Intervention: Collaborative Care (enhanced management of pharmacotherapy and brief psychoeducational interventions)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Collaborative Care (brief cognitive-behavioral therapy and enhanced patient education)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 370
Study: 8175505

Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.5 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg)
Number of subjects: 9
Study: 6493047

Group type: EXPERIMENTAL
Intervention: Stediril-d 150/30 (150 micrograms levo-norgestrel and 30 micrograms ethinylestradiol)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ministat (750 micrograms lynestrenol and 37.5 micrograms ethinylestradiol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 30474147

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sprint Interval Exercise (SIE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Repeated-Sprint Exercise (RSE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All forms of acute interval exercise
Number of subjects: 36
Study: 29496472

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg once per day
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study: 27631563

Group type: EXPERIMENTAL
Intervention: Sexual enhancement program with weekly follow‐ups
Number of subjects: 104

Group type: COMPARATOR
Intervention: General educational material on postmenopause
Number of subjects: 104
Study: 25456807

Group type: EXPERIMENTAL
Intervention: School food exposure (adolescents surveyed while school was in session)
Number of subjects: 1542

Group type: COMPARATOR
Intervention: No school food exposure (adolescents surveyed when school was not in session)
Number of subjects: 1542
Study: 23071510

Group type: EXPERIMENTAL
Intervention: Specific music exposure during sleeping hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: No music exposure (Control group)
Number of subjects: 0
Study: 20171409

Group type: EXPERIMENTAL
Intervention: Active patch containing 10% methyl salicylate and 3% l-menthol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Active patch
Number of subjects: 208
Study: 17384176

Group type: EXPERIMENTAL
Intervention: Low-dose deflazacort (DFZ) 7.5 mg for 6 months, followed by methyl prednisolone (MP) 4 mg for 6 months.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methyl prednisolone (MP) 4 mg for 6 months, followed by low-dose deflazacort (DFZ) 7.5 mg for 6 months.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Group II vs Group I at 3 months showed a reduction of OPG (24% vs 6%, P = n.s.).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups from the sixth month.
Number of subjects: 21
Study: 17310221

Group type: EXPERIMENTAL
Intervention: Rosiglitazone treatment for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched controls (obese normoglycemic patients, n=10)
Number of subjects: 10